Glenmark Pharmaceuticals Sees Surge in Call Option Activity Ahead of March Expiry

Call Option Activity Highlights

On 10 March 2026, Glenmark Pharmaceuticals witnessed the most active call option trading among its peers, with 7,917 contracts exchanged at the ₹2200 strike price expiring later this month. This surge in activity generated a turnover of ₹1919.08 lakhs, underscoring robust investor interest in leveraged bullish bets. The open interest stood at 757 contracts, indicating sustained positions rather than short-term speculative trades.

The underlying stock price closed at ₹2221.0, comfortably above the ₹2200 strike, suggesting that option buyers are positioning for further upside. The proximity to the strike price enhances the intrinsic value potential of these calls, making them attractive for traders anticipating continued momentum.

Price Performance and Technical Strength

Glenmark’s stock price has demonstrated notable strength, touching an intraday high of ₹2222 on the day of heightened options activity, marking a 4.93% gain. It currently trades just 3.24% below its 52-week high of ₹2284.8, signalling resilience and a potential breakout zone. The stock outperformed its sector by 3.25% and the broader Sensex by 4.22% on the same day, reflecting strong relative strength.

Technically, Glenmark is trading above all key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — which confirms a sustained uptrend. This technical backdrop supports the bullish positioning evident in the options market and aligns with the company’s recent upgrade from a Strong Buy to a Buy rating by MarketsMOJO on 6 June 2025, with a Mojo Score of 78.0.

Market Capitalisation and Sector Context

With a market capitalisation of ₹61,342 crores, Glenmark is classified as a mid-cap stock within the Pharmaceuticals & Biotechnology sector. Despite its mid-cap status, the company’s liquidity remains robust, with a delivery volume of 1.2 lakh shares on 9 March 2026, although this represented a 47.32% decline against the five-day average delivery volume. Nevertheless, the stock’s liquidity supports trade sizes up to ₹1.75 crore based on 2% of the five-day average traded value, facilitating sizeable institutional and retail participation.

Investor Sentiment and Expiry Dynamics

The concentration of call option contracts at the ₹2200 strike price with expiry on 30 March 2026 suggests that investors are positioning for a near-term rally. The open interest of 757 contracts, while not excessively large, indicates that many traders are holding onto their bullish bets rather than closing positions, which often precedes a price move in the underlying stock.

Given the underlying value of ₹2221.0, the call options are slightly in-the-money, enhancing their appeal as a leveraged instrument to capitalise on further gains. This pattern is consistent with a market consensus that Glenmark’s fundamentals and technicals support continued appreciation in the coming weeks.

Fundamental and Quality Assessment

MarketsMOJO’s upgrade of Glenmark Pharmaceuticals from Strong Buy to Buy on 6 June 2025 reflects a nuanced view of the company’s prospects. The Mojo Score of 78.0 remains robust, signalling strong fundamentals and quality metrics, although the slight downgrade suggests some moderation in growth expectations or valuation concerns. The company’s market cap grade of 2 indicates mid-cap status, which often entails higher volatility but also greater growth potential compared to large caps.

Within the Pharmaceuticals & Biotechnology sector, Glenmark’s performance outpaces many peers, supported by solid earnings growth, pipeline developments, and strategic initiatives. The sector’s 1-day return of 1.24% on 10 March 2026 pales in comparison to Glenmark’s 4.75% gain, highlighting the stock’s leadership role.

Implications for Investors

The pronounced call option activity at the ₹2200 strike price, combined with Glenmark’s strong technical positioning and sector outperformance, suggests that investors are optimistic about the stock’s near-term trajectory. Traders utilising options are effectively leveraging their bullish outlook, expecting the stock to breach recent highs and potentially test or surpass the ₹2284.8 52-week peak.

However, the decline in delivery volume by 47.32% compared to the five-day average indicates some caution among long-term holders or a rotation of capital. This mixed signal warrants close monitoring of volume trends and price action in the coming sessions.

For investors considering exposure to Glenmark Pharmaceuticals, the current environment offers a compelling risk-reward profile, supported by strong fundamentals, positive technical signals, and active derivatives market participation. The company’s mid-cap status and sector leadership further enhance its appeal for growth-oriented portfolios.

Expiry Outlook and Strategic Considerations

With the 30 March 2026 expiry approaching, the concentration of call option contracts at the ₹2200 strike price may lead to increased volatility as traders adjust positions. Should the stock maintain or extend gains above this level, option holders stand to benefit from intrinsic value appreciation, potentially driving further buying interest.

Conversely, any pullback below the strike price could prompt profit-taking or position unwinding, impacting price dynamics. Investors should weigh these factors alongside broader market conditions and sector trends when formulating strategies.

Conclusion

Glenmark Pharmaceuticals Ltd. is currently at the centre of bullish market activity, as evidenced by its dominant call option trading and strong price performance. The stock’s technical strength, combined with a solid fundamental backdrop and a favourable Mojo Score, supports a positive outlook. While some caution is warranted due to fluctuating delivery volumes, the overall sentiment remains constructive heading into the March expiry.

Market participants and investors should continue to monitor option open interest, strike price concentrations, and price momentum to capitalise on potential opportunities in this mid-cap pharmaceutical leader.

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →